Advertisement
Advertisement
Grand-Rue 90, Montreux 1820, Switzerland
PHONE: +41 21 966 12 01
| Company Name | Product Name | Nominal Pressure (atm) | Rated Burst Pressure (atm) | Guidewire Compatibility (inch) | Shaft Length (cm) | Sheath Compatibility (F) | Balloon Diameters (mm) | Balloon Lengths (cm) |
|---|---|---|---|---|---|---|---|---|
| Stryker | Gateway PTA Balloon Catheter | 6 | 12, 14 (for 2.25–3.25 mm only) | – | 136 | 6 | 1.5, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4 | 9, 15, 20 |
Advertisement
Advertisement
| Company Name | Product Name | Sheath Compatibility (F) | Guidewire Compatibility (inch) | Working Length (cm) | Mode of Operation | CE Mark Indications |
|---|---|---|---|---|---|---|
| Stryker | Trevo NXT ProVue Retriever; 3 X 25, 4 X 21, 4 X 35, and 6 X 30 mm | 8, 9 (balloon guide catheter) | 0.014 | 200 for all stent sizes | Mechanical thrombectomy; 360° of consistently large cells, a soft distal tip, and full-length radiopacity | (1) Indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA); endovascular therapy with the device should start within 6 hours of symptom onset; (2) intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset; patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment; (3) indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 segments with smaller core infarcts (0-50 mL for age < 80 years, 0-20 mL for age ≥ 80 years); endovascular therapy with the device should start within 6 to 24 hours of time last seen well in patients who are ineligible for IV t-PA or who fail IV t-PA therapy |
| Stryker | Trevo XP ProVue Retriever; 3 X 20, 4 X 20, 4 X 30, 6 X 25 mm | 8, 9 (balloon guide catheter) | 0.014 | 190 for 3 X 20 mm; 180 for 4 X 20 mm, 4 X 30 mm, and 6 X 25 mm | Mechanical thrombectomy; 360° of consistently large cells, a soft distal tip and full-length radiopacity | Indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large-vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA); endovascular therapy with the device should start within 6 hours of symptom onset; intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset; patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment Indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large-vessel occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 segments with smaller-core infarcts (0–50 mL for age < 80 years, 0–20 mL for age ≥ 80 years); endovascular therapy with the device should start within 6–24 hours of time last seen well in patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy |
More Categories:
Aortic (AAA) Aortic (TAA) Balloons Catheters Embolization Sheaths Stents Wires Other Devices View AllAdvertisement
© 2026 Bryn Mawr Communications II, LLC.
All Rights Reserved • Privacy Policy